secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unity Biotechnology, Inc. (—)
CIK:        0001463361
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0000950170-25-091210
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unity Biotechnology to dissolve; Nasdaq delisting effective July 9, 2025
------------------------------------------------------------------------

- Board approved Plan of Dissolution; stockholder vote required before filing certificate of dissolution.
- Nasdaq notified company it no longer has an operating business; stock will be suspended July 9, 2025; company will not appeal.
- All eight directors resigned; Craig R. Jalbert appointed sole director, President, and principal executive/financial/accounting officer.
- CEO Anirvan Ghosh, CFO Lynne Sullivan, and CLO Alexander Nguyen departed effective June 27.
- Company had previously implemented substantial reduction in force and closed its Phase 2b ASPIRE study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025091210/0000950170-25-091210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1463361/000095017025091210/ubx-20250627.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-091210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer